Abstracts

Poster Presentation Dates

All odd numbered posters will be presented on Friday, November 8, 2019, while even numbered posters will be presented on Saturday, November 9, 2019.

Posters will be on display from 7 a.m. - 8 p.m., with the presenting authors required to be at their posters during lunch (12:30 - 2 p.m. on Friday, Nov. 8, and 12:35 - 2:05 p.m. on Saturday, Nov. 9) and also during the poster reception (6:30 - 8p.m. on Friday, Nov. 8, and 7 - 8:30 p.m. on Saturday, Nov. 9).

#	Title	Authors	Category	Keywords
P441	ARTISTRY-2: a phase 1/2 study of subcutaneously administrated ALKS 4230 as monotherapy and in combination with pembrolizumab in patients with advanced solid tumors	John D. Powderly, II, MD, CPI; Bradley C. Carthon, MD, PhD; Marc S. Ernstoff, MD; Anthony J. Olszanski, MD, RPh; Stephen V. Liu, MD; Kelly K. Curtis, MD; Yangchun Du, PhD; Lei Sun, PhD; Emily L. Putiri, PhD; Yan Wang, PhD; Heather C. Losey, PhD; Bruce J. Dezube, MD; Ulka N. Vaishampayan, MD;	Clinical Trial In Progress	Checkpoint blockade; Cytokine; Immune suppression; NK/NK T cell; Regulatory T cell (Treg cell); Solid tumors
P447	ALKS 4230, an engineered IL-2 fusion protein, in monotherapy dose-escalation and combination therapy with pembrolizumab in patients with solid tumors: ARTISTRY-1 trial	Ulka N. Vaishampayan, MD; Jameel Muzaffar, MD; Vamsidhar Velcheti, MD, FACP; Christopher J. Hoimes, DO; Lucy Gilbert, MD; David F. McDermott, MD; Anna Spreafico, MD PhD; Quincy Chu, MD; Kelly K. Curtis, MD; Yangchun Du, PhD; Harald Mackenzie, MB; Lei Sun, PhD; Emily L. Putiri, PhD; Heather C. Losey, PhD; Bruce J. Dezube, MD; Marc S. Ernstoff, MD;	Clinical Trial In Progress	Checkpoint blockade; Cytokine; Immune suppression; NK/NK T cell; Regulatory T cell (Treg cell); Solid tumors